 Connection
Steven Rosenberg to Treatment Outcome
This is a "connection" page, showing publications Steven Rosenberg has written about Treatment Outcome.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.356 |
|
|
|
-
Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 05; 42(4):126-135.
Score: 0.058
-
Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329.
Score: 0.051
-
Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015 May 15; 21(10):2278-88.
Score: 0.043
-
Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015 Mar 01; 21(5):1019-27.
Score: 0.043
-
Tran E, Rosenberg SA. T-cell therapy against cancer mutations. Oncotarget. 2014 Jul 15; 5(13):4579-80.
Score: 0.042
-
Wiggins LD, Nadler C, Rosenberg S, Moody E, Reyes N, Reynolds A, Alexander A, Daniels J, Thomas K, Giarelli E, Levy SE. Many Young Children with Autism Who Use Psychotropic Medication Do Not Receive Behavior Therapy: A Multisite Case-Control Study. J Pediatr. 2021 05; 232:264-271.
Score: 0.016
-
Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019 03 01; 25(5):1486-1493.
Score: 0.014
-
Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. J Immunother. 2018 Jun; 41(5):241-247.
Score: 0.014
-
Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, Schrump DS, Rosenberg SA, Sherry RM. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Ann Surg Oncol. 2017 Jan; 24(1):135-141.
Score: 0.012
-
Prickett TD, Crystal JS, Cohen CJ, Pasetto A, Parkhurst MR, Gartner JJ, Yao X, Wang R, Gros A, Li YF, El-Gamil M, Trebska-McGowan K, Rosenberg SA, Robbins PF. Durable Complete Response from Metastatic Melanoma after Transfer of Autologous T Cells Recognizing 10 Mutated Tumor Antigens. Cancer Immunol Res. 2016 08; 4(8):669-78.
Score: 0.012
-
Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res. 2015 Feb 01; 21(3):534-43.
Score: 0.011
-
Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, Goldman CK, Bryant BR, Decker JM, Chen J, Worthy TA, Figg WD, Peer CJ, Sneller MC, Lane HC, Yovandich JL, Creekmore SP, Roederer M, Waldmann TA. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol. 2015 Jan 01; 33(1):74-82.
Score: 0.011
-
Watkins S, Jonsson-Funk M, Brookhart MA, Rosenberg SA, O'Shea TM, Daniels J. Preschool motor skills following physical and occupational therapy services among non-disabled very low birth weight children. Matern Child Health J. 2014 May; 18(4):821-8.
Score: 0.010
-
Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 01; 120(9):1426-32.
Score: 0.010
-
Watkins S, Jonsson-Funk M, Brookhart MA, Rosenberg SA, O'Shea TM, Daniels J. An empirical comparison of tree-based methods for propensity score estimation. Health Serv Res. 2013 Oct; 48(5):1798-817.
Score: 0.010
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|